Association of Immune Checkpoint Inhibitor Therapy With Survival in Patients With Cancers With MUC16 Variants

JAMA Netw Open. 2020 Jun 1;3(6):e205837. doi: 10.1001/jamanetworkopen.2020.5837.

Abstract

This cohort study investigates whether MUC16 variation could be a useful biomarker for immune checkpoint inhibitor (ICI) therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Biomarkers, Tumor / genetics
  • CA-125 Antigen / genetics*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Female
  • Genetic Variation
  • Humans
  • Kaplan-Meier Estimate
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Male
  • Melanoma / drug therapy
  • Melanoma / genetics
  • Membrane Proteins / genetics*
  • Middle Aged
  • Neoplasms / drug therapy*
  • Neoplasms / genetics*
  • Progression-Free Survival
  • Proportional Hazards Models
  • Survival Rate

Substances

  • Antineoplastic Agents, Immunological
  • Biomarkers, Tumor
  • CA-125 Antigen
  • MUC16 protein, human
  • Membrane Proteins